The transformation of community oncology provides behavior analysts with a compelling case study in how policy turbulence, consolidation, and reimbursement changes reshape healthcare delivery — dynamics that are increasingly relevant to the ABA industry. While the specific clinical content of oncology falls outside the behavior analyst's scope of practice, the structural forces described in this presentation mirror challenges that ABA organizations face: rapid spending growth, evolving regulatory frameworks, consolidation of independent practices into larger entities, and the constant tension between cost containment and quality care.
Provider: BehaviorLive — via AVBCC
Take This Course →Including ethics, supervision, and topics like this one. New live CEU every Wednesday.
Join Free →Independent oncology practices have undergone seismic shifts over the past several years, driven by rapid consolidation, evolving reimbursement models and a dynamic regulatory environment. While drug distribution remains a critical component of the oncology supply chain, this panel will explore a broader and more urgent question: What does the future hold for community oncology in an era of uncertainty and innovation? Between 2019 and 2023, U.S. oncology drug spending surged from $65 billion to $99 billion, with projections reaching $180 billion by 2028. This growth is fueled by an aging population, rising cancer incidence and the proliferation of high-cost immunotherapies and precision treatments. Yet, the infrastructure supporting independent oncology is under pressure. The number of community practices declined from 1,638 in 2021 to 1,555 in 2023, with rural access shrinking and clinical trial availability unevenly distributed. This panel brings together leaders from Cardinal Health, Cencora and McKesson for a conversation about their shared commitment to sustaining high-quality cancer care in the community. Together, they will discuss: How distributors are evolving to support independent practices through value-based care, clinical innovation and operational resilience;The impact of recent acquisitions on care delivery and patient outcomes;Strategies to preserve access, equity and excellence in oncology amid shifting policy and payment landscapes; and Opportunities for collaboration across the supply chain to ensure that patients receive timely, affordable and effective treatment close to home.
| Certification Body | Credits | Type |
|---|---|---|
| BACB | 1 | Ethics |
Dig into the research behind this topic — plain-English summaries written for BCBAs.
188 research articles with practitioner takeaways
152 research articles with practitioner takeaways
133 research articles with practitioner takeaways
You earn CEUs from a dozen different places. Upload any certificate — from here, your employer, conferences, wherever — and always know exactly where you stand. Learning, Ethics, Supervision, all handled.
No credit card required. Cancel anytime.
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.